Payment overview · 2025
General Payments
$107.60
6 reported records · 6 companies
Healthcare provider profile · identity verified
Danny Wayne Mcfall, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FLORENCE, AL · NPI 1023129814
Verified facts
What the public records show
CMS Open Payments records show Danny Wayne Mcfall, MD received $107.60 in general payments during 2025 across 6 reported records.
Novo Nordisk Inc accounted for 23.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.82 | 23.1% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.17 | 17.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.63 | 17.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.77 | 14.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.16 | 14.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.05 | 13.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $107.60 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 87 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 161 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 151 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
87 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
161 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
151 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 970 | 257 |
| Levothyroxine Sodium | Levothyroxine Sodium | 728 | 180 |
| Potassium Chloride | Potassium Chloride | 700 | 196 |
| Omeprazole | Omeprazole | 609 | 162 |
| Gabapentin | Gabapentin | 600 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 583 | 175 |
| Losartan Potassium | Losartan Potassium | 547 | 147 |
| Pantoprazole Sodium | Pantoprazole Sodium | 506 | 130 |
| Eliquis | Apixaban | 452 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 428 | 124 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 356 | 90 |
| Tramadol Hcl | Tramadol Hcl | 356 | 82 |
| Metformin Hcl | Metformin Hcl | 342 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 334 | 96 |
| Sertraline Hcl | Sertraline Hcl | 318 | 78 |
| Furosemide | Furosemide | 275 | 85 |
| Fluticasone Propionate | Fluticasone Propionate | 265 | 102 |
| Hydrochlorothiazide | Hydrochlorothiazide | 261 | 71 |
| Escitalopram Oxalate | Escitalopram Oxalate | 253 | 64 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 224 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 213 | 52 |
| Clonazepam | Clonazepam | 210 | 37 |
| Lisinopril | Lisinopril | 207 | 52 |
| Metformin Hcl Er | Metformin Hcl | 190 | 62 |
| Pravastatin Sodium | Pravastatin Sodium | 185 | 51 |
| Meloxicam | Meloxicam | 181 | 54 |
| Montelukast Sodium | Montelukast Sodium | 180 | 44 |
| Buspirone Hcl | Buspirone Hcl | 175 | 36 |
| Simvastatin | Simvastatin | 175 | 47 |
| Lorazepam | Lorazepam | 174 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 167 | 41 |
| Allopurinol | Allopurinol | 164 | 51 |
| Jardiance | Empagliflozin | 161 | 33 |
| Ozempic | Semaglutide | 151 | 32 |
| Alprazolam | Alprazolam | 142 | 27 |
| Spironolactone | Spironolactone | 138 | 36 |
| Atenolol | Atenolol | 134 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 134 | 38 |
| Glipizide | Glipizide | 129 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 127 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 38 |
| Meclizine Hcl | Meclizine Hcl | 122 | 29 |
| Trazodone Hcl | Trazodone Hcl | 121 | 29 |
| Prednisone | Prednisone | 116 | 49 |
| Azithromycin | Azithromycin | 113 | 93 |
| Donepezil Hcl | Donepezil Hcl | 111 | 24 |
| Ezetimibe | Ezetimibe | 100 | 29 |
| Irbesartan | Irbesartan | 93 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 91 | 43 |
| Labetalol Hcl | Labetalol Hcl | 89 | 28 |
| Benazepril Hcl | Benazepril Hcl | 88 | 23 |
| Mounjaro | Tirzepatide | 88 | 19 |
| Farxiga | Dapagliflozin Propanediol | 87 | 16 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 85 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 85 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 33 |
| Warfarin Sodium | Warfarin Sodium | 84 | 19 |
| Valsartan | Valsartan | 80 | 17 |
| Carvedilol | Carvedilol | 79 | 23 |
| Finasteride | Finasteride | 77 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 76 | 62 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 76 | 19 |
| Diazepam | Diazepam | 75 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 73 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 69 | 18 |
| Chlorthalidone | Chlorthalidone | 67 | 19 |
| Naproxen | Naproxen | 67 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 65 | 19 |
| Mirtazapine | Mirtazapine | 65 | 25 |
| Memantine Hcl | Memantine Hcl | 64 | 15 |
| Clonidine Hcl | Clonidine Hcl | 60 | 17 |
| Xarelto | Rivaroxaban | 59 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 56 | 38 |
| Famotidine | Famotidine | 55 | 13 |
| Pregabalin | Pregabalin | 55 | 15 |
| Torsemide | Torsemide | 54 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 53 | 12 |
| Lansoprazole | Lansoprazole | 53 | 11 |
| Synthroid | Levothyroxine Sodium | 53 | suppressed |
| Aripiprazole | Aripiprazole | 52 | suppressed |
| Methocarbamol | Methocarbamol | 52 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 17 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 49 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 49 | 11 |
| Colestipol Hcl | Colestipol Hcl | 48 | 17 |
| Ondansetron Odt | Ondansetron | 47 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | suppressed |
| Entresto | Sacubitril/Valsartan | 44 | suppressed |
| Nadolol | Nadolol | 44 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 42 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 20 |
| Cephalexin | Cephalexin | 41 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Cefdinir | Cefdinir | 40 | 28 |
| Fluconazole | Fluconazole | 40 | 17 |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 38 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | 24 |
| Valacyclovir | Valacyclovir Hcl | 37 | 11 |
| Linzess | Linaclotide | 36 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 36 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Methylprednisolone | Methylprednisolone | 35 | 30 |
| Ramipril | Ramipril | 35 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 35 | 12 |
| Amoxicillin | Amoxicillin | 33 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 14 |
| Ibuprofen | Ibuprofen | 33 | 19 |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 33 |
| Repatha Sureclick | Evolocumab | 33 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 18 |
| Temazepam | Temazepam | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | 12 |
| Colesevelam Hcl | Colesevelam Hcl | 29 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 27 | suppressed |
| Sotalol | Sotalol Hcl | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | 12 |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 16 |
| Nystatin | Nystatin | 17 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 13 |
| Glimepiride | Glimepiride | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 14 | 14 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $107.60 · 6 records | Novo Nordisk Inc | FARXIGA, JARDIANCE, Kerendia, NEXLETOL, Ozempic, REXULTI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error